Lightwave Logic Provides Test Update on Perkinamine NR Optical Material

Lightwave Logic, Inc. (OTC Bulletin Board: LWLG) a technology company focused on the development of the 'Next Generation Electro-Optic Polymer Material Platform' for applications in high speed fiber-optic data communications and optical computing, provided an update on the Company's work with Lehigh University physicists on third-order nonlinear optical properties of its proprietary molecule, Perkinamine NR™.

Third-order optical nonlinearities do not require an electric field to influence the passage of light through a material.  This property has led this evolving technology area to be known as light- switching-light optical technology. Lehigh has tested thin-film polymer composites of Perkinamine NR™ and determined the following third-order effects:

  • 100 times stronger than the highest off-resonance small molecule currently known.
  • 2600 times more powerful than fused silica, the general on resonance response measurement standard.
  • Extremely fast (less than 1 picosecond) photo-induced nonlinear response that would be capable of modulation at rates of 1 THz (terahertz).

Lightwave's Chief Technology Officer, David Eaton stated, "The Lehigh University team's tests demonstrate that the potential applications for our materials portfolio can be greatly expanded outside the telecom arena. We are excited to be working with Professor Ivan Biaggio and his team."

Jim Marcelli, Lightwave's Chief Executive Officer added, "We believe that these tests establish the unique properties of our exciting Perkinamine NR™ optical material which holds the promise of ultra-fast optical switches, optical computing applications and computational data transfer."

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.